Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-25-000057
Filing Date
2025-01-21
Accepted
2025-01-21 20:33:09
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 29829
2 AGREEMENT exh-1_18923.htm EX-1 47224
3 POWER OF ATTORNEY exh-2_18923.htm EX-2 26732
  Complete submission text file 0001072613-25-000057.txt   105611
Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities Fund IV, LLC (Filed by) CIK: 0001644965 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE
Business Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE 011-44-0-2032834200
Verona Pharma plc (Subject) CIK: 0001657312 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-89843 | Film No.: 25543669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)